Therapeutic Advances in Cardiovascular Disease最新文献

{"title":"Artificial intelligence for cardiology: from diagnosis to management.","authors":"Vasanthrie Naidoo, Lavanya Madamshetty, Suresh Babu Naidu Krishna","doi":"10.1177/17539447251406847","DOIUrl":"10.1177/17539447251406847","url":null,"abstract":"<p><p>Artificial intelligence (AI) and machine learning are rapidly transforming cardiac electrophysiology, offering new avenues for diagnosing, managing, and treating cardiac arrhythmias. These technologies leverage diverse data sources, including clinical records, imaging, and electrical waveforms, to support decision-making and optimize outcomes, particularly in procedures such as cardiac ablation. This scoping review explores the evolving role of AI in cardiology, emphasizing its applications in diagnostics, predictive analytics, and procedural innovations. It also examines the collaborative dynamics of interdisciplinary teams, highlighting how professionals, such as electrophysiologists, computer scientists, clinicians, nurses, perfusionists, and technologists, contribute to identifying and solving key challenges in the field. The integration of AI into cardiology is not only enhancing diagnostic precision and patient outcomes but also streamlining healthcare delivery. As technological capabilities expand, AI is poised to play an increasingly central role in preventive cardiology, enabling more accurate risk assessments, earlier interventions, and the promotion of healthier lifestyles. However, the successful implementation of AI requires thoughtful coordination across disciplines and a clear understanding of its limitations and ethical considerations. This review underscores the importance of fostering interdisciplinary collaboration and aligning AI innovations with clinical needs. It also identifies barriers to adoption and proposes strategies for integrating AI tools into routine practice. Ultimately, the findings aim to guide stakeholders, including researchers, clinicians, and policymakers, in advancing the development and application of AI systems in cardiology. By doing so, the healthcare community can move toward reducing the global burden of cardiovascular disease and improving population health. The insights presented here, after a review of 142 studies, offer a roadmap for future research and clinical integration, ensuring that AI continues to serve as a catalyst for innovation and excellence in cardiac care.</p>","PeriodicalId":23035,"journal":{"name":"Therapeutic Advances in Cardiovascular Disease","volume":"20 ","pages":"17539447251406847"},"PeriodicalIF":3.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12923939/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146221182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on \"Neurological efficacy and safety of RNA therapeutics in hereditary transthyretin amyloidosis: a systematic review and meta-analysis of randomized controlled trials\".","authors":"Ankur Sharma, Varshini Vadhithala, Arun Kumar, Sushma Verma, Sushma Narsing Katkuri","doi":"10.1177/17539447261453501","DOIUrl":"10.1177/17539447261453501","url":null,"abstract":"","PeriodicalId":23035,"journal":{"name":"Therapeutic Advances in Cardiovascular Disease","volume":"20 ","pages":"17539447261453501"},"PeriodicalIF":3.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13195210/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147983293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing cardiovascular imaging in Iraq: infrastructure, gender diversity, and future perspectives.","authors":"Hasan Ali Farhan, May Saad Al-Jorani","doi":"10.1177/17539447261418111","DOIUrl":"10.1177/17539447261418111","url":null,"abstract":"<p><p>Cardiovascular imaging (CVI) provides an essential and accurate assessment of cardiac anatomy, function, and prognosis, thereby guiding management planning in long-term illnesses. It plays an essential role in modern cardiology in Iraq, where the adoption of advanced CVI technologies has enhanced diagnostic precision and patient care. However, there are some limitations that may interrupt the specialized improvement process, including a shortage of specialized personnel, limited infrastructure, and economic barriers. To address these challenges, the Iraqi Council of Cardiology established a nationally accredited CVI fellowship program in 2019. The key feature to initiate the program is the deliberate integration of diversity, particularly gender and geographic representation, into the training framework. This approach yielded a significantly high participation of women in CVI compared to other cardiology subspecialties in Iraq, which eventually reflected a special regional trend and productive response to workforce gaps. Also, geographic diversity has widened access to expertise across governorates, supporting equitable healthcare delivery. Regardless of these advances, marked progress needs continued investment in infrastructure and alignment with international standards. Furthermore, expanding and strengthening research capacity and fostering international collaborations will be critical to advance the whole process. The Iraqi CVI program has illustrated the framework of policy, training, and workforce planning that will overcome systemic limitations and contribute to the advancement of equitable cardiovascular care in resource-limited settings.</p>","PeriodicalId":23035,"journal":{"name":"Therapeutic Advances in Cardiovascular Disease","volume":"20 ","pages":"17539447261418111"},"PeriodicalIF":3.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12936369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147284917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two-year real-world outcomes of coronary drug-coated balloon therapy: a retrospective comparative study of sirolimus- and paclitaxel-coated devices.","authors":"Enes Alıç, Mohamed Niang, Haşim Tüner, Mehdi Onaç, Ahmad Kashur, Emrah Ermiş, Sinem Özbay Özyılmaz, Hakan Uçar","doi":"10.1177/17539447261463654","DOIUrl":"10.1177/17539447261463654","url":null,"abstract":"<p><strong>Background: </strong>Drug-coated balloons (DCBs) represent a \"leave-nothing-behind\" strategy in percutaneous coronary intervention (PCI), particularly for small vessel disease and in-stent restenosis. However, long-term comparative real-world data between paclitaxel- and sirolimus-coated balloons remain limited, and the impact of lesion characteristics on outcomes is not fully understood.</p><p><strong>Objectives: </strong>This study aimed to evaluate the 2-year clinical outcomes of coronary DCB therapy and compare the performance of sirolimus- and paclitaxel-coated balloons in a real-world cohort.</p><p><strong>Design: </strong>Single-center retrospective cohort study.</p><p><strong>Methods: </strong>A total of 92 consecutive patients who underwent DCB-based PCI between January 2020 and December 2022 were retrospectively analyzed. Patients were grouped according to DCB type (sirolimus vs paclitaxel). The primary endpoints were restenosis, target lesion revascularization (TLR), and major adverse cardiac events (MACE), defined as a composite of cardiac death, myocardial infarction, and TLR. Secondary outcomes included changes in angina frequency and severity, and selected laboratory parameters. Outcomes were assessed over 24-month follow-up period.</p><p><strong>Results: </strong>The overall 2-year restenosis rate was 13.0%, with TLR occurring in 7.6% of patients, and MACE in 9.8%. Significant improvements in angina frequency and severity were observed at 3 months (both <i>p</i> < 0.001). C-reactive protein (CRP) levels decreased during follow-up (<i>p</i> = 0.01). Patients with diabetes had numerically higher rates of restenosis (15.0% vs 11.0%) and MACE (12.5% vs 9.6%) compared with nondiabetic patients, although differences were not statistically significant. Similarly, sirolimus-coated balloons were associated with lower rates of restenosis (11.7% vs 15.6%) and TLR (6.7% vs 9.4%) compared with paclitaxel-coated balloons, without statistical significance. Larger vessel diameter was associated with an increased risk of restenosis (<i>p</i> = 0.004).</p><p><strong>Conclusion: </strong>In this real-world cohort, coronary DCB therapy was associated with acceptable 2-year clinical outcomes and significant symptom improvement. Although sirolimus-coated balloons showed numerically favorable results, no definitive conclusions regarding superiority can be drawn. Larger prospective studies are needed to confirm these findings and to better define optimal patient and lesion selection.</p><p><strong>Trial registration: </strong>Not applicable.</p>","PeriodicalId":23035,"journal":{"name":"Therapeutic Advances in Cardiovascular Disease","volume":"20 ","pages":"17539447261463654"},"PeriodicalIF":3.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13380677/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148498074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"35 Years of modern cardiothoracic surgery in Ghana: a legacy of excellence, a future of perfection.","authors":"Kow Entsua-Mensah, George Ekem-Ferguson, Mark Mawutor Tettey, Martin Tamatey, Innocent Adzamli","doi":"10.1177/17539447261445309","DOIUrl":"10.1177/17539447261445309","url":null,"abstract":"<p><p>The National Cardiothoracic Centre at the Korle Bu Teaching Hospital stands as a premier institution for cardiothoracic surgery in Ghana and West Africa. Established in 1989 under the leadership of Prof. Kwabena Frimpong-Boateng, the Centre recently celebrated 35 years of advancing modern cardiothoracic surgery in Ghana. The Centre also serves as an accredited training hub for cardiothoracic surgeons, critical care nurses and other allied health professionals in the West African sub-region. Over the past 35 years, the Centre has undertaken 14,981 surgeries and other cardiac procedures for Ghanaians and other African countries. The centre has also locally trained a total of 30 cardiothoracic surgeons for Ghana, Nigeria and Ethiopia, and has recently commenced training its first surgeon for the Gambia. Among the Centres' challenges are infrastructural deficit, limited health financing, human resource deficit and technological gaps. This narrative review highlights the Centre's 35 years of existence, its contributions to the cardiothoracic surgical landscape in West Africa, challenges and its future directions.</p>","PeriodicalId":23035,"journal":{"name":"Therapeutic Advances in Cardiovascular Disease","volume":"20 ","pages":"17539447261445309"},"PeriodicalIF":3.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13167317/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Accra to Kampala: Ghana's cardiothoracic legacy and the unfinished agenda for rheumatic heart disease in East Africa.","authors":"Kaweesi Calvin Nantalaga","doi":"10.1177/17539447261490746","DOIUrl":"10.1177/17539447261490746","url":null,"abstract":"","PeriodicalId":23035,"journal":{"name":"Therapeutic Advances in Cardiovascular Disease","volume":"20 ","pages":"17539447261490746"},"PeriodicalIF":3.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569993/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148945724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel predictor of short-term prognosis in acute pulmonary embolism: inflammatory burden index.","authors":"Lingwei Huang, Dan Xiao, Meimei Yang, Zixing Wu, Fei He","doi":"10.1177/17539447251407467","DOIUrl":"10.1177/17539447251407467","url":null,"abstract":"<p><strong>Background: </strong>Inflammation significantly impacts disease progression and prognosis in acute pulmonary embolism (APE); however, the optimal method to quantify this inflammation for prognostic purposes remains unclear.</p><p><strong>Objectives: </strong>We aimed to identify the most effective blood-based inflammatory marker for predicting short-term mortality in patients with APE.</p><p><strong>Methods: </strong>We retrospectively analyzed 301 patients with APE. We compared the predictive performance of nine inflammatory markers for 30-day mortality, focusing on the inflammatory burden index (IBI), and contrasted it with the standard clinical score (sPESI).</p><p><strong>Results: </strong>After adjusting for potential confounders, a higher IBI was strongly and independently associated with an increased risk of 30-day mortality. IBI demonstrated superior predictive ability compared with all other inflammatory markers and the sPESI score. The relationship between IBI and mortality risk was linear; higher IBI values corresponded to greater mortality risk.</p><p><strong>Conclusion: </strong>IBI is a robust and independent predictor of short-term survival in patients with APE. Calculated from routine blood tests (C-reactive protein, neutrophil, and lymphocyte counts), it offers a simple, rapid, and cost-effective tool that may enhance early risk stratification and guide personalized treatment decisions in clinical practice. Further validation in independent cohorts is required to confirm its prognostic utility.</p>","PeriodicalId":23035,"journal":{"name":"Therapeutic Advances in Cardiovascular Disease","volume":"20 ","pages":"17539447251407467"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12764757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145893020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Troponins and echocardiography: role in detecting myocardial injury in burn patients.","authors":"Mohammed AbuBaha, Samia Aldwaik, Ameer Awashra, Fathi Milhem, Anwar Zahran, Husam Hamshary, Hasan Fuqha, Mohammad Bdair, Bara Abubaha, Sarah Saife, Abdalhakim Shubietah","doi":"10.1177/17539447251414564","DOIUrl":"10.1177/17539447251414564","url":null,"abstract":"<p><p>Severe burn injuries result in a massive systemic inflammatory and hypermetabolic response, often disrupting multiple organ systems, including the cardiovascular system. Cardiac troponins are frequently elevated in burn patients, but the interpretation of these elevations is hardly straightforward. Sometimes, elevated troponin means type 1 myocardial infarction (MI) due to an acute coronary event, but it might also reflect type 2 MI due to an imbalance between body oxygen demand and supply, or even non-ischemic myocardial injury from things like overwhelming inflammation, sepsis, or direct thermal effects on the heart itself. This narrative review explores the prevalence, underlying pathophysiological mechanisms, diagnostic challenges, and prognostic implications of troponin elevation in burn patients. We discussed the limitations of applying conventional MI diagnostic criteria in this unique population. The role of electrocardiographic and echocardiographic assessment, as well as the potential utility of high-sensitivity troponin assays, is also discussed. Understanding of how burn pathophysiology relates to myocardial injury is essential for accurate diagnosis, improved management, and better outcomes in this highly vulnerable group of patients.</p>","PeriodicalId":23035,"journal":{"name":"Therapeutic Advances in Cardiovascular Disease","volume":"20 ","pages":"17539447251414564"},"PeriodicalIF":3.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12833205/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146044104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The pivotal role of echocardiography in structural heart interventions: from planning to success.","authors":"Tuğba Kemaloğlu Öz, Michael Hii, Deniz Kemaloglu, Ahmed Mohamed Fareed, Konstantinos Papadopoulos, Edoardo Zancanaro, Anosh Shane Sivashanmugarajah, Majo Joseph","doi":"10.1177/17539447251412630","DOIUrl":"10.1177/17539447251412630","url":null,"abstract":"<p><p>Structural heart disease (SHD) encompasses a wide range of congenital and acquired cardiac abnormalities, increasingly treated with transcatheter interventions. Echocardiography plays a crucial role in optimising these procedures, providing high-resolution imaging for pre-procedural planning, real-time guidance and post-intervention assessment. The shift from two-dimensional to advanced three/four-dimensional (3D/4D) echocardiography has significantly enhanced the visualisation of complex cardiac structures, improving procedural success and patient safety. The purpose of this review article is to provide an overview of the vital role of echocardiography in key structural heart interventions, including mitral transcatheter edge-to-edge repair, transcatheter aortic valve replacement, paravalvular leak closure, left atrial appendage occlusion and atrial septal defect closure. It highlights the integration of 3D/4D imaging and advanced Doppler techniques in refining procedural precision, optimising decision-making, and improving patient outcomes. The evolving field of interventional echocardiography continues to shape SHD management, making more minimally invasive treatments available to patients.</p>","PeriodicalId":23035,"journal":{"name":"Therapeutic Advances in Cardiovascular Disease","volume":"20 ","pages":"17539447251412630"},"PeriodicalIF":3.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12924934/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146259274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world effectiveness and safety of torsemide and spironolactone fixed dose combination in Indian heart failure patients (RESTORE-HF study): a prospective, multicenter, observational study.","authors":"Chandrashekhar K Ponde, Devanu Ghosh Roy, Uday Jadav, Arun Mohanty, Karan Dang, Febin Francis, Nitin Zalte, Amarnath Sugumaran, Sandesh Sawant, Senthilnathan Mohanasundaram","doi":"10.1177/17539447261430243","DOIUrl":"10.1177/17539447261430243","url":null,"abstract":"<p><strong>Background: </strong>Heart failure (HF) remains a major public health challenge in India, with a need for effective and well-tolerated therapeutic strategies.</p><p><strong>Objective: </strong>The RESTORE-HF study evaluated the real-world effectiveness and safety of torsemide-spironolactone fixed-dose combination (FDC) in Indian patients with HF.</p><p><strong>Design: </strong>Prospective, multicenter, observational study.</p><p><strong>Methods: </strong>This study was conducted across 101 sites in India. Patients aged 18-75 years with HF with reduced ejection fraction and signs of congestion were enrolled and initiated on the torsemide-spironolactone FDC. Participants were followed over 3 weeks from baseline. The primary objective was the change in body weight. Secondary endpoints included changes in New York Heart Association (NYHA) functional class, edema, occurrence of adverse events (AEs), and physician and patient assessments of efficacy and tolerability.</p><p><strong>Results: </strong>Of the 1841 patients screened, 1752 were enrolled, and 1520 completed the study. The mean (SD) age of participants was 58.61 (9.45) years, of whom 61.05% were male. The study showed a significant reduction in mean body weight was observed from 75.54 kg at baseline to 73.13 kg at week 3 (mean difference: 2.41 kg; <i>p</i> < 0.0001). Additionally, an improvement in NYHA functional class and edema was observed over 3 weeks from baseline. Overall, 22.11% patients achieved no-edema stage. Only three mild AEs related to loose stools were reported, and no serious AEs or deaths occurred. Over 98% of physicians and patients rated the therapy favorably.</p><p><strong>Conclusion: </strong>The RESTORE-HF study demonstrated that the torsemide-spironolactone FDC may be associated with a mean body weight reduction of 2.41 kg and may be generally well-tolerated in Indian heart failure patients. Furthermore, the FDC may be linked to significant symptomatic improvement over 3 weeks in real-world clinical practice.</p>","PeriodicalId":23035,"journal":{"name":"Therapeutic Advances in Cardiovascular Disease","volume":"20 ","pages":"17539447261430243"},"PeriodicalIF":3.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13010024/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147469272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}